Literature DB >> 27932288

Pressure ulcer as a reservoir of multiresistant Gram-negative bacilli: risk factors for colonization and development of bacteremia.

Iolanda A Braga1, Cristiane S Brito2, Augusto Diogo Filho1, Paulo P Gontijo Filho3, Rosineide M Ribas3.   

Abstract

The purpose of this study was to identify the risk factors that predispose patients who are hospitalized with pressure ulcers (PUs) colonized by Gram-negative bacilli (GNB) to develop bacteremia. In addition, we also detected main phenotypes of resistance in infected and uninfected PUs. A prospective cohort study was conducted at the Clinical Hospital of the Federal University of Uberlândia including patients with Stage II or greater PUs, colonized or not with GNB, from August 2009 to July 2010. Infected ulcers were defined based on clinical signs and on positive evaluation of smears of wound material translated by a ratio of polymorphonuclear cells to epithelial cells ≥2:1, after Giemsa staining. A total of 60 patients with Stage II PUs were included. Of these 83.3% had PUs colonized and/or infected. The frequency of polymicrobial colonization was 74%. Enterobacteriaceae and GNB non-fermenting bacteria were the most frequent isolates of PUs with 44.0% of multiresistant isolates. Among patients who had infected PUs, six developed bacteremia by the same microorganism with a 100% mortality rate. In addition, PUs in hospitalized patients were major reservoir of multiresistant GNB, also a high-risk population for the development of bacteremia with high mortality rates.
Copyright © 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. All rights reserved.

Entities:  

Keywords:  Bacteremia; Colonization; Gram-negative bacilli; Pressure ulcer

Mesh:

Year:  2016        PMID: 27932288      PMCID: PMC9427655          DOI: 10.1016/j.bjid.2016.11.007

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   3.257


Introduction

Pressure ulcer (PUs) is a common clinical problem associated with high cost in terms of both treatment and human suffering. This is particularly common in elderly patients in general hospitals and home care settings, mainly in critical units where its incidence ranges from 8% to 40%. The microbiota of PUs is usually polymicrobial and complex and can be colonized with Gram-negative bacilli (GNB) multidrug-resistant and methicillin-resistant Staphylococcus aureus (MRSA). PUs can be reservoirs for resistant microorganisms and may evolve into local infections, also becoming a source of bacteremia in hospitalized patients. This study aimed to identify the risk factors that predispose hospitalized patients with PUs colonized by GNB to develop bacteremia by these microorganisms. In addition, we also detected the main phenotypes of bacterial resistance in infected and uninfected PUs.

Materials and methods

Setting and study design

The research was conducted at the Clinical Hospital of the Federal University of Uberlândia, a tertiary 510-bed teaching hospital, from August 2009 to July 2010. During the study period, 60 patients with Stage II or greater PUs were included in a prospective cohort study, whose medical records were identified by active surveillance and reviewed for demographic and risk factor data.

Definitions

Infected PU

The presence of infection at the ulcer site was based on clinical signs and symptoms (i.e., erythema, edema, pain, foul odor, and purulent exudates, fever, delayed healing, discoloration of granulation tissue, friable granulation tissue, and wound breakdown).5, 6 In addition, a PU was deemed infected when the smear of its material yielded a ratio of polymorphonuclear to squamous epithelial cells ≥2:1 after Giemsa staining.

PU staging

PUs were classified according to the criteria proposed by Santos et al.

Bacteremia

Defined as the presence of viable bacteria in the blood documented by a positive blood culture. Only the first MRSA and GNB bacteremia episode was taken into consideration.

Multidrug-resistant (MDR) phenotype

The criteria used for defining MDR phenotype was: non-susceptible to ≥1 agent of ≥3 antimicrobial classes.

Specimen collection and microbiological techniques

PU cleaning was performed with sterile and warm saline solution (around 37.5 °C) and an aseptic technique under irrigation pressure with a syringe (20 ml) and needle (gauges 25X8-21). Afterwards, a sterile swab moistened with saline solution was rotated over a 1 cm2 area of granulation tissue with sufficient pressure to press fluid out of the wound tissue. The clinical specimen was inoculated into MacConkey Agar, and the differentiation of Gram-negative microorganisms in Enterobacteriaceae family and non-fermenting bacilli was made through oxidation-fermentation (OF) and oxidase tests. For Enterobacteriaceae it was used glucose and lactose fermentation; indole production; motility; citrate; urea hydrolysis; sulfidric gas production; phenylalanine deaminase; lysine and ornithine decarboxylase; methyl red reaction; and Voges-Proskauer test. For non-fermenting GNB it was used nitrate reduction; gluconate use; pigment production; lysine decarboxylase activity; urease activity; indole production; acetamide and esculin hydrolysis. The swab was inoculated into Mannitol Agar, and Staphylococcus aureus was identified as coagulase-positive by classic techniques. Selected S. aureus and GNB isolates were evaluated using the disk diffusion test for resistance to methicillin and fluoroquinolones, and to third and fourth generation cephalosporins and carbapenems, respectively. Quality-control protocols were used according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2014).

Ethical aspects

Ethical approval was obtained from the Ethics Committee of Uberlandia Federal University according to the requirements of the Ministry of Health, under protocol numbers 333/09 and 118/05.

Statistical analysis

To assess the association of risk factors with bacteremia, patients with infected and uninfected PU were compared using the Student's t-test for continuous data and the Fisher exact test or chi-square test for categorical data, when appropriate. A p-value less than or equal to 0.05 was considered significant. Statistical analyses were performed with GraphPad Prism version 4 (GraphPad Software, San Diego, CA).

Results

A total of 60 patients were investigated. 117 patients were excluded due to Stage I PUs or because the patients and/or family members have not agreed to participate in this study. The patients were predominantly men (70.0%), mean age of 61 years with a wide range (20–88 years). The majority of patients were hospitalized for clinical reasons (53.3%) or trauma (26.7%). Only six (10.0%) patients were admitted because of infected PUs. The patients were hospitalized for an average of 103 days (SD ± 84.8 days). Cardiomyopathy (78.3%) and diabetes mellitus (43.3%) were the most common comorbidities. Gastrointestinal catheter (85.0%), central venous catheter (55.0%), mechanical ventilation (45.0%), urinary catheter (40.0%), three or more invasive devices (55.0%), and three or more classes of antimicrobial agents (77.9%) were used by most of the patients. The hospital mortality rate was also high (41.7%) in this cohort (data not shown). Enterobacteriaceae were the most commonly isolated (49.0%) group of bacteria in colonized/infected patients with PUs, followed by Staphylococcus aureus (28.0%) and non-fermenting GNB (23.0%), mostly Pseudomonas aeruginosa and Acinetobacter spp. Colonization with multiresistant bacteria including Klebsiella pneumoniae (17/20, 85.0%), Escherichia coli (6/24, 25.0%), Enterobacter (1/4, 25.0%), Pseudomonas aeruginosa (18/18, 100.0%), Acinetobacter spp. (3/5, 60.0%), and methicillin-resistant Staphylococcus aureus (17/28, 60.7%) were the predominant bacteria in our patients. The frequency of epidemiologically relevant phenotypes such as fluoroquinolones- and carbapenems-resistant Pseudomonas aeruginosa, carbapenems-resistant Acinetobacter spp, third generation cephalosporins-resistant Klebsiella pneumoniae, and Escherichia coli were surpassed 40% among GNB isolates. Among the 16 patients with infected PUs, 35 samples were isolated of which 29 (82.9%) were multiresistant bacteria, whereas among 34 patients with non-infected PUs, 65 samples were isolated, of which 35 (52.3%) were multiresistant (Table 1). By univariate analysis, no risk factors were statistically associated with GNB bacteremia in patients with Stage II or greater PUs colonized by these pathogens (data not shown).
Table 1

Microorganisms and resistance phenotypes in isolated pressure ulcers.

Microorganisms/phenotypesTotal isolates of PUaIsolated of infected PUIsolated of no infected PU
N = 100 (%)N = 35 (%)N = 65 (%)
Enterobacteriaceae49 (49.0)16 (45.7)33 (50.8)
 Escherichia coli24 (49.0)7 (43.8)17 (51.5)
  Resistant to 3rd generation cephalosporins10 (41.7)7 (100.0)3 (17.6)
  Resistant to fluoroquinolones7 (29.2)5 (71.4)2 (11.8)
  Multiresistant6 (25.0)2 (28.6)4 (23.5)
 Klebsiella pneumoniae20 (40.8)8 (50.0)12 (36.4)
  Resistant to 3rd/4th generation cephalosporins17 (85.0)7 (87.5)10 (83.3)
  Multiresistant17 (85.0)7 (87.5)10 (83.3)
 Enterobacter spp.4 (8.2)1 (6.3)3 (9.1)
  Resistant to 3rd generation cephalosporins4 (100.0)1 (100.0)3 (100.0)
  Multiresistant1 (25.0)1 (100.0)0
 Proteus spp.1 (2.0)01 (3.0)
  Resistant to 3rd generation cephalosporins1 (100.0)01 (100.0)
  Multiresistant1 (100.0)01 (100.0)



Non-fermenting GNB23 (23.0)14 (40.0)9 (13.8)
 Pseudomonas aeruginosa18 (78.3)11 (78.6)7 (77.8)
  Resistant to 3rd generation cephalosporins18 (100.0)11 (100.0)7 (100.0)
  Resistant to carbapenems7 (38.9)6 (54.5)1 (14.3)
  Resistant to fluoroquinolones8 (44.4)6 (54.4)2 (28.6)
  Multiresistant18 (100.0)11 (100.0)7 (100.0)
 Acinetobacter spp.5 (21.7)3 (21.4)2 (22.2)
  Resistant to 3rd generation cephalosporins5 (100.0)3 (100.0)2 (100.0)
  Resistant to carbapenems3 (60.0)3 (100.0)0
  Multiresistant3 (60.0)3 (100.0)0
 Staphylococcus aureus28 (28.0)5 (14.3)23 (35.4)
  MRSAb17 (60.7)5 (100.0)12 (52.2)

Pressure ulcer.

Methicillin-resistant Staphylococcus aureus.

Microorganisms and resistance phenotypes in isolated pressure ulcers. Pressure ulcer. Methicillin-resistant Staphylococcus aureus. Of the 50 patients (83.3%) with PU colonized by GNB, 16 (32.0%) developed local infections. Out of these 16 patients with infected ulcer, 10 patients (62.5%) developed bacteremia. Among these 10 patients, six had the same isolates recovered from both exudate and blood with similar phenotype/antibiotic susceptibility pattern. The mortality in this group of patients with PU infected with GNB bacteremia was higher (OR: 7.43, 95% CI, 1.23–45.0, p = 0.04) than in patients with non-infected PUs (Table 2).
Table 2

Bacteremia in patients with pressure ulcers colonized by Gram-negative bacilli.

Infected pressure ulcerNon-infected pressure ulcerp-valueaORb (95% CI)
N = 16 (%)N = 34 (%)
Bacteremia10 (62.5)20 (58.8)0.801.17 (0.34–3.96)
 Concordancec6 (60.0)5 (25.0)0.104.50 (0.89–22.75)
 Death8 (80.0)7 (35.0)0.047.43 (1.23–45.0)

Statistical significance at 5%.

Odds ratio (95% confidence interval).

Phenotypic concordance between the organism in the blood and ulcer.

Bacteremia in patients with pressure ulcers colonized by Gram-negative bacilli. Statistical significance at 5%. Odds ratio (95% confidence interval). Phenotypic concordance between the organism in the blood and ulcer.

Discussion

Pressure ulcers are a public health problem that results in distress and disability, and constitute a great challenge to health administrators. They are particularly common among elderly patients in general hospitals and home care settings. Our study included 60 patients with Stage II or greater PUs with characteristics of critically ill patients, the majority with three or more invasive procedures (55.0%) and two or more comorbidities (75.0%). In addition, these patients had a rather long length of hospital stay (mean 103 days) and a high hospital mortality rate (41.7%). Stage III PUs were the most common (32.0%) in our series. PUs are also frequently colonized by several species of bacteria and surface cultures yield a polymicrobial flora of both Gram-positive and Gram-negative aerobic and anaerobic species. The microorganisms most commonly isolated in chronic wounds are usually Staphylococcus aureus, β-hemolytic Streptococci, Enterococcus spp., aerobic GNB Enterobacteriaceae and Pseudomonas spp., and in particular, resistant bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., ciprofloxacin-resistant Pseudomonas aeruginosa, and extended-spectrum beta-lactamase (Escherichia coli and Citrobacter).16, 17 In our study, 50 out of 60 patients (83.3%) had PUs with cultures positive for GNB, most with mixed flora (74.0%). Most isolates were identified as Enterobacteriaceae (49.0%), Escherichia coli (49.0%) and Klebsiella pneumoniae (40.8%), and non-fermenting GNB (23.0%), mainly Pseudomonas aeruginosa (78.3%), and Staphylococcus aureus (28.0%). A total of 63% of the isolates were multiresistant to different antibiotics, including Pseudomonas aeruginosa (100.0%), Proteus spp. (100.0%), Klebsiella spp (85.0%), MRSA (60.7%), Acinetobacter spp (60.0%), Escherichia coli (25.0%), and Enterobacter spp. (25.0%). One of the few reports in the literature about the role of polymicrobial synergy in local wound infection pointed out that the recovered bacteria from PUs are similar to those of acute necrotizing soft tissue infections, namely anaerobic and aerobic bacteria, thus likely contributing to the deterioration of a lesion. Our results confirming that the polymicrobial flora was observed in the majority (74.0%) of infected wounds are in line with the findings of that report. The association of PUs with bacteremia is well established, but few studies have addressed this problem systematically. PUs may serve as occult foci for blood stream infection, the most common major complication of PUs. Infected PUs are more likely to cause bacteremia than wounds only colonized with polymicrobial microorganisms, also evident in our results. In hospitalized patients, the relationship between bacteremia and PU has been associated with 50% mortality rate. Among 21 patients with sepsis attributed solely to PU, bacteremia was documented in 16 (76%) cases, and 47.6% of the patients died, eight of these despite appropriate antibiotics treatment. Our data showed that out of 16 patients with infected PUs, 10 (62.5%) developed GNB bacteremia, six had the same microorganism isolated from the PU and blood. Out of these six, Pseudomonas aeruginosa was recovered from four patients and Klebsiella pneumoniae from two. In our study, the 16 patients with bacteremia caused by the same GNB that was recovered from the PU had a higher risk of dying (OR = 7.43; p ≤ 0.04) when compared with 34 patients who did not have infected PUs and were just colonized by these microorganisms. The hospital mortality rate was 80.0% in patients with infected PUs who developed bacteremia, compared to 35.0% in those who developed bacteremia, but had no infected PUs in spite of the presence of the same microorganism in PUs and blood. In conclusion, Stage II or greater PUs in hospitalized patients are reservoirs of multiresistant GNB, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Colonization of PUs was predominantly polymicrobial with significant association with infection in other anatomic sites. This study also emphasizes the importance of PUs as a potential source of bacteremia in hospitalized patients leading to high mortality rates.

Conflicts of interest

The authors declare no conflicts of interest.
  13 in total

Review 1.  Wound microbiology and associated approaches to wound management.

Authors:  P G Bowler; B I Duerden; D G Armstrong
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  The quantitative swab culture and smear: A quick, simple method for determining the number of viable aerobic bacteria on open wounds.

Authors:  N S Levine; R B Lindberg; A D Mason; B A Pruitt
Journal:  J Trauma       Date:  1976-02

3.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

4.  Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.

Authors:  Raquel Cavalcanti Dantas; Melina Lorraine Ferreira; Paulo Pinto Gontijo-Filho; Rosineide Marques Ribas
Journal:  J Med Microbiol       Date:  2014-09-26       Impact factor: 2.472

Review 5.  Biofilm-infected pressure ulcers: current knowledge and emerging treatment strategies.

Authors:  Louise Suleman; Steven L Percival
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

6.  Criteria for identifying wound infection.

Authors:  K F Cutting; K G Harding
Journal:  J Wound Care       Date:  1994-06-02       Impact factor: 2.072

7.  Colonization of pressure ulcers by multidrug-resistant microorganisms in patients receiving home care.

Authors:  Maria Concetta Cataldo; Celestino Bonura; Giuseppe Caputo; Aurora Aleo; Giovanna Rizzo; Daniela Maria Geraci; Cinzia Calá; Teresa Fasciana; Anna Rita Mattaliano; Caterina Mammina
Journal:  Scand J Infect Dis       Date:  2011-07-05

8.  Sepsis associated with decubitus ulcers.

Authors:  J E Galpin; A W Chow; A S Bayer; L B Guze
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

9.  Bacteriological investigation of infected pressure ulcers in spinal cord-injured patients and impact on antibiotic therapy.

Authors:  B Heym; F Rimareix; A Lortat-Jacob; M-H Nicolas-Chanoine
Journal:  Spinal Cord       Date:  2004-04       Impact factor: 2.772

Review 10.  World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections.

Authors:  Massimo Sartelli; Mark A Malangoni; Addison K May; Pierluigi Viale; Lillian S Kao; Fausto Catena; Luca Ansaloni; Ernest E Moore; Fred A Moore; Andrew B Peitzman; Raul Coimbra; Ari Leppaniemi; Yoram Kluger; Walter Biffl; Kaoru Koike; Massimo Girardis; Carlos A Ordonez; Mario Tavola; Miguel Cainzos; Salomone Di Saverio; Gustavo P Fraga; Igor Gerych; Michael D Kelly; Korhan Taviloglu; Imtiaz Wani; Sanjay Marwah; Miklosh Bala; Wagih Ghnnam; Nissar Shaikh; Osvaldo Chiara; Mario Paulo Faro; Gerson Alves Pereira; Carlos Augusto Gomes; Federico Coccolini; Cristian Tranà; Davide Corbella; Pietro Brambillasca; Yunfeng Cui; Helmut A Segovia Lohse; Vladimir Khokha; Kenneth Yy Kok; Suk-Kyung Hong; Kuo-Ching Yuan
Journal:  World J Emerg Surg       Date:  2014-11-18       Impact factor: 5.469

View more
  11 in total

1.  Compositions and antimicrobial properties of binary ZnO-CuO nanocomposites encapsulated calcium and carbon from Calotropis gigantea targeted for skin pathogens.

Authors:  G Ambarasan Govindasamy; Rabiatul Basria S M N Mydin; Srimala Sreekantan; Nor Hazliana Harun
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

2.  An Integrated HOCl-Producing E-Scaffold Is Active against Monomicrobial and Polymicrobial Biofilms.

Authors:  Laure Flurin; Yash S Raval; Abdelrhman Mohamed; Kerryl E Greenwood-Quaintance; Edison J Cano; Haluk Beyenal; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Transmission of resistant Gram-negative bacteria to healthcare personnel gowns and gloves during care of residents in community-based nursing facilities.

Authors:  Natalia Blanco; J Kristie Johnson; John D Sorkin; Alison D Lydecker; Lauren Levy; Lona Mody; Mary-Claire Roghmann
Journal:  Infect Control Hosp Epidemiol       Date:  2018-10-08       Impact factor: 3.254

4.  Bactericide effect of methylene blue associated with low-level laser therapy in Escherichia coli bacteria isolated from pressure ulcers.

Authors:  Thais Ferreira Gomes; Matheus Masalskiene Pedrosa; Ana Claudia Laforga de Toledo; Veridiana Wanshi Arnoni; Mirian Dos Santos Monteiro; Davi Cury Piai; Silvia Helena Zacarias Sylvestre; Bruno Ferreira
Journal:  Lasers Med Sci       Date:  2018-05-09       Impact factor: 3.161

5.  Metabolic Profiling of VOCs Emitted by Bacteria Isolated from Pressure Ulcers and Treated with Different Concentrations of Bio-AgNPs.

Authors:  Fernanda Monedeiro; Viorica Railean-Plugaru; Maciej Monedeiro-Milanowski; Paweł Pomastowski; Bogusław Buszewski
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

6.  Distinct Skin Microbiome and Skin Physiological Functions Between Bedridden Older Patients and Healthy People: A Single-Center Study in Japan.

Authors:  Satoshi Nagase; Kazuhiro Ogai; Tamae Urai; Kana Shibata; Emi Matsubara; Kanae Mukai; Miki Matsue; Yumiko Mori; Miku Aoki; Defa Arisandi; Junko Sugama; Shigefumi Okamoto
Journal:  Front Med (Lausanne)       Date:  2020-04-08

7.  Subeschar culture using a punch instrument in unstageable wounds.

Authors:  Han Byul Jung; Yong Jig Lee
Journal:  Arch Plast Surg       Date:  2020-05-15

8.  Skin-stretching device promotes the treatment effect of vacuum sealing drainage technique on phases III and IV stress-induced injuries in aged patients with chronic critical illness: A retrospective study of 70 patients.

Authors:  Fulian Zhang; Yuecheng Gu; Linjun Wu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

9.  Bacteremia associated with pressure ulcers: a prospective cohort study.

Authors:  Elena Espejo; Marta Andrés; Rosa-Maria Borrallo; Emma Padilla; Enric Garcia-Restoy; Feliu Bella
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-26       Impact factor: 3.267

10.  Evaluation of ebselen in resolving a methicillin-resistant Staphylococcus aureus infection of pressure ulcers in obese and diabetic mice.

Authors:  Haroon Mohammad; Nader S Abutaleb; Alexandra M Dieterly; L Tiffany Lyle; Mohamed N Seleem
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.